Fundamental Analysis of SOLID BIOSCIENCES INC(NASDAQ:SLDB) stock

Fundamental Rating

SLDB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. While SLDB seems to be doing ok healthwise, there are quite some concerns on its profitability. SLDB does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SLDB has reported negative net income.

In the past year SLDB has reported a negative cash flow from operations.

In the past 5 years SLDB always reported negative net income.

In the past 5 years SLDB always reported negative operating cash flow.

1.2 Ratios

SLDB has a Return On Assets of -58.21%. This is comparable to the rest of the industry: SLDB outperforms 42.83% of its industry peers.

SLDB has a Return On Equity (-75.91%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-58.21%
ROE	-75.91%
ROIC	N/A

ROA(3y)-40.77%

ROA(5y)-57.43%

ROE(3y)-50.4%

ROE(5y)-72.91%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLDB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SLDB does not have a ROIC to compare to the WACC, probably because it is not profitable.

SLDB has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, SLDB has more shares outstanding

SLDB has a worse debt/assets ratio than last year.

2.2 Solvency

SLDB has an Altman-Z score of -0.87. This is a bad value and indicates that SLDB is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of SLDB (-0.87) is comparable to the rest of the industry.

SLDB has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.

SLDB has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: SLDB outperforms 45.73% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	-0.87

ROIC/WACCN/A

WACC9.12%

2.3 Liquidity

A Current Ratio of 8.94 indicates that SLDB has no problem at all paying its short term obligations.

SLDB has a Current ratio of 8.94. This is in the better half of the industry: SLDB outperforms 77.30% of its industry peers.

SLDB has a Quick Ratio of 8.94. This indicates that SLDB is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of SLDB (8.94) is better than 77.47% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.94
Quick Ratio	8.94

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SLDB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.43%, which is quite impressive.

Looking at the last year, SLDB shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.

EPS 1Y (TTM)60.43%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q64.54%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

SLDB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.77% yearly.

Based on estimates for the next years, SLDB will show a very strong growth in Revenue. The Revenue will grow by 134.56% on average per year.

EPS Next Y43.49%

EPS Next 2Y18.84%

EPS Next 3Y14.54%

EPS Next 5Y12.77%

Revenue Next Year370.81%

Revenue Next 2Y130.28%

Revenue Next 3Y41.89%

Revenue Next 5Y134.56%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLDB. In the last year negative earnings were reported.

Also next year SLDB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as SLDB's earnings are expected to grow with 14.54% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y18.84%

EPS Next 3Y14.54%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

SLDB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SOLID BIOSCIENCES INC

NASDAQ:SLDB (5/3/2024, 7:18:36 PM)

10.1

-0.13 (-1.27%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap382.39M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-58.21%
ROE	-75.91%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	8.94
Quick Ratio	8.94
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)60.43%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y43.49%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

SOLID BIOSCIENCES INC (SLDB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens